Rhythm Biosciences (FRA:0RY) Piotroski F-Score: 4 (As of Jun. 26, 2026) — 33% Above Median


FRA:0RY Rhythm Biosciences Ltd FRA:0RY
31 GF Score
Price €0.05
! 6 Warning Signs
View Full Analysis

What is Rhythm Biosciences Piotroski F-Score?

Rhythm Biosciences FRA:0RY +0.93% 31 Piotroski F-Score is 4 as of Jun. 26, 2026, which is 33% above its 10-year median of 3.00. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 6 warning signs investors should review. Among 211 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 51.18% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rhythm Biosciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Rhythm Biosciences's Piotroski F-Score or its related term are showing as below:

FRA:0RY' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 4
Current: 4

During the past 8 years, the highest Piotroski F-Score of Rhythm Biosciences was 4. The lowest was 2. And the median was 3.

Rhythm Biosciences  (FRA:0RY) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Rhythm Biosciences Piotroski F-Score Related Terms


Rhythm Biosciences Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Rhythm Biosciences's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rhythm Biosciences Piotroski F-Score Chart

Rhythm Biosciences Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Piotroski F-Score
Get a 7-Day Free Trial 2.00 2.00 3.00 2.00 4.00

Rhythm Biosciences Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 2.00 0.00 4.00 0.00

FRA:0RY vs TMO, DHR, IDXX: Piotroski F-Score Comparison

For the Diagnostics & Research subindustry, Rhythm Biosciences's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rhythm Biosciences Piotroski F-Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Rhythm Biosciences's Piotroski F-Score falls into.


FRA:0RY
31GF Score
Rhythm Biosciences Ltd FRA:0RY
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun25) TTM:Last Year (Jun24) TTM:
Net Income was €-2.16 Mil.
Cash Flow from Operations was €-1.65 Mil.
Revenue was €0.01 Mil.
Gross Profit was €-0.11 Mil.
Average Total Assets from the begining of this year (Jun24)
to the end of this year (Jun25) was (0.937 + 1.599) / 2 = €1.268 Mil.
Total Assets at the begining of this year (Jun24) was €0.94 Mil.
Long-Term Debt & Capital Lease Obligation was €0.00 Mil.
Total Current Assets was €1.02 Mil.
Total Current Liabilities was €1.22 Mil.
Net Income was €-4.23 Mil.

Revenue was €0.00 Mil.
Gross Profit was €0.00 Mil.
Average Total Assets from the begining of last year (Jun23)
to the end of last year (Jun24) was (4.767 + 0.937) / 2 = €2.852 Mil.
Total Assets at the begining of last year (Jun23) was €4.77 Mil.
Long-Term Debt & Capital Lease Obligation was €0.05 Mil.
Total Current Assets was €0.55 Mil.
Total Current Liabilities was €0.35 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rhythm Biosciences's current Net Income (TTM) was -2.16. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Rhythm Biosciences's current Cash Flow from Operations (TTM) was -1.65. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun24)
=-2.161/0.937
=-2.30629669

ROA (Last Year)=Net Income/Total Assets (Jun23)
=-4.23/4.767
=-0.88735053

Rhythm Biosciences's return on assets of this year was -2.30629669. Rhythm Biosciences's return on assets of last year was -0.88735053. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Rhythm Biosciences's current Net Income (TTM) was -2.16. Rhythm Biosciences's current Cash Flow from Operations (TTM) was -1.65. ==> -1.65 > -2.16 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=0.001/1.268
=0.00078864

Gearing (Last Year: Jun24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun23 to Jun24
=0.052/2.852
=0.01823282

Rhythm Biosciences's gearing of this year was 0.00078864. Rhythm Biosciences's gearing of last year was 0.01823282. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun25)=Total Current Assets/Total Current Liabilities
=1.023/1.219
=0.83921247

Current Ratio (Last Year: Jun24)=Total Current Assets/Total Current Liabilities
=0.547/0.347
=1.57636888

Rhythm Biosciences's current ratio of this year was 0.83921247. Rhythm Biosciences's current ratio of last year was 1.57636888. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Rhythm Biosciences's number of shares in issue this year was 269.252. Rhythm Biosciences's number of shares in issue last year was 228.297. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.113/0.014
=-8.07142857

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0/0
=

Rhythm Biosciences's gross margin of this year was -8.07142857. Rhythm Biosciences's gross margin of last year was . ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun24)
=0.014/0.937
=0.0149413

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun23)
=0/4.767
=0

Rhythm Biosciences's asset turnover of this year was 0.0149413. Rhythm Biosciences's asset turnover of last year was 0. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Rhythm Biosciences has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 4 mean?
Rhythm Biosciences (FRA:0RY) has a Piotroski F-Score of 4 as of Jun. 26, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Rhythm Biosciences and its competitors. This is 33% above median its historical median of 3.00. Over the past decade, Rhythm Biosciences' Piotroski F-Score has ranged from 2.00 to 4.00. According to the industry distribution chart, Rhythm Biosciences ranks #108 out of 211 companies in the Medical Diagnostics & Research industry, placing it in the top 51.2%.
Is Rhythm Biosciences' Piotroski F-Score too high?
Rhythm Biosciences' current Piotroski F-Score of 4 is 33% above median its 10-year median of 3.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 4.00. The Medical Diagnostics & Research industry median Piotroski F-Score is 5.00. Rhythm Biosciences' value of 4 is 20% below this industry median. Based on the distribution chart, Rhythm Biosciences ranks #108 out of 211 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' Piotroski F-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #108 out of 211 companies for Piotroski F-Score. This places Rhythm Biosciences in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Rhythm Biosciences' value of 4 is 20% below this benchmark. Historically, Rhythm Biosciences' own Piotroski F-Score has ranged from 2.00 to 4.00 over the past decade. While the company's 10-year median is 3.00 vs. the industry median of 5.00, Rhythm Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Diagnostics & Research company?
The median Piotroski F-Score among Medical Diagnostics & Research companies is 5.00, based on 211 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rhythm Biosciences's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current Piotroski F-Score is 4, which is 33% above median its own 10-year median of 3.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current Piotroski F-Score of 4. The current Piotroski F-Score is 4, which is 33% above median its 10-year median of 3.00 and 20% below the Medical Diagnostics & Research industry median of 5.00. Rhythm Biosciences' overall GF Score™ is 31/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current Piotroski F-Score is 4 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rhythm Biosciences Business Description

Other Exchanges RHY:Australia
Address 30 Flemington Road, Bio21 Institute, Parkville, Melbourne, VIC, AUS, 3010
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score

Get the complete analysis for FRA:0RY

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.05
Price